Legal & General Group PLC Humanigen, Inc Transaction History

Legal & General Group PLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.15 - $3.02 $7,417 - $149,339	-49,450 Closed	0 $0
Q2 2022 Aug 22, 2022	BUY	$1.76 - $3.33 $48,917 - $92,554	27,794 Added 128.34%	49,450 $87,000
Q1 2022 May 16, 2022	BUY	$1.81 - $3.97 $117 - $258	65 Added 0.3%	21,656 $65,000
Q4 2021 Feb 14, 2022	BUY	$3.66 - $8.22 $10,493 - $23,566	2,867 Added 15.31%	21,591 $80,000
Q3 2021 Nov 15, 2021	BUY	$5.93 - $17.83 $37,697 - $113,345	6,357 Added 51.4%	18,724 $111,000
Q2 2021 Aug 12, 2021	BUY	$13.54 - $22.74 $167,449 - $281,225	12,367 New	12,367 $214,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.